Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation

Figure 2

Relapse after treatment discontinuation is independent of trough serum adalimumab levels. Trough serum adalimumab levels at the end of treatment (2 weeks after the last injection) were similar between patients who did and those who did not relapse after discontinuation of the tumour necrosis factor inhibitor (TNFi) (A) Median (interquartile range). Neither was there a correlation between the drug levels and time to relapse (B).

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us